556 related articles for article (PubMed ID: 15013721)
21. [COX-2].
Oh-ishi S
Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1109-13. PubMed ID: 10771681
[No Abstract] [Full Text] [Related]
22. [Cyclooxygenase 2 inhibitors and lung carcinoma].
Spano JP; Chouahnia K; Morère JF
Bull Cancer; 2004 May; 91 Spec No():S109-12. PubMed ID: 15239338
[TBL] [Abstract][Full Text] [Related]
23. [Cyclooxygenase-2 (COX-2) in digestive cancer. Therapeutic implications].
Bessa X; Piñol V; Elizalde JI; Castells A
Gastroenterol Hepatol; 2000 Dec; 23(10):483-90. PubMed ID: 11149225
[No Abstract] [Full Text] [Related]
24. [Clinical pharmacology of selective inhibitors of cyclooxygenase-2].
Patrignani P
Acta Otorhinolaryngol Ital; 2003 Aug; 23(4 Suppl 74):13-8, 37-40. PubMed ID: 15058604
[No Abstract] [Full Text] [Related]
25. Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?
Koga H
Cancer; 2003 Aug; 98(4):661-7. PubMed ID: 12910508
[TBL] [Abstract][Full Text] [Related]
26. Development of COX inhibitors in cancer prevention and therapy.
Umar A; Viner JL; Anderson WF; Hawk ET
Am J Clin Oncol; 2003 Aug; 26(4):S48-57. PubMed ID: 12902856
[TBL] [Abstract][Full Text] [Related]
27. COX-2 inhibitors: a review.
Houston AM; Teach SJ
Pediatr Emerg Care; 2004 Jun; 20(6):396-9; quiz 400-2. PubMed ID: 15179150
[No Abstract] [Full Text] [Related]
28. COX-2 inhibitors as radiosensitizing agents for cancer therapy.
Davis TW; Hunter N; Trifan OC; Milas L; Masferrer JL
Am J Clin Oncol; 2003 Aug; 26(4):S58-61. PubMed ID: 12902857
[TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenease-2 and hepatocellular carcinoma: is it a target for prevention?
DuBois RN
Clin Cancer Res; 2001 May; 7(5):1110-1. PubMed ID: 11350871
[No Abstract] [Full Text] [Related]
30. Aspirin and the prevention of colorectal cancer.
Berman KS
N Engl J Med; 2003 Jun; 348(24):2466-7; author reply 2466-7. PubMed ID: 12803217
[No Abstract] [Full Text] [Related]
31. Why cyclooxygenase-2 inhibition plus chemotherapy?
Sweeney CJ
Am J Clin Oncol; 2003 Aug; 26(4):S122-5. PubMed ID: 12902869
[TBL] [Abstract][Full Text] [Related]
32. Aspirin use and potential mechanisms for colorectal cancer prevention.
Williams CS; Smalley W; DuBois RN
J Clin Invest; 1997 Sep; 100(6):1325-9. PubMed ID: 9294096
[No Abstract] [Full Text] [Related]
33. [Selective COX-2 inhibitors for therapy of rheumatoid arthritis].
Sano H
Nihon Rinsho; 2005 Jan; 63 Suppl 1():477-87. PubMed ID: 15799403
[No Abstract] [Full Text] [Related]
34. [Current topics in the regulation of prostanoids-1. Inducible cyclooxygenase COX-2 and selective blockers].
Ohara M; Sawa T
Masui; 1998 Nov; 47(11):1325-32. PubMed ID: 9852696
[TBL] [Abstract][Full Text] [Related]
35. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?
Warner TD; Mitchell JA
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13371-3. PubMed ID: 12374850
[No Abstract] [Full Text] [Related]
36. [Prostanoids and acute lung injury].
Kudoh I; Ohara M; Sawa T
Masui; 2002 Jun; 51(6):598-604. PubMed ID: 12134647
[TBL] [Abstract][Full Text] [Related]
37. The cost of COX inhibitors: how selective should we be?
Marra CA; Esdaile JM; Sun H; Anis AH
J Rheumatol; 2000 Dec; 27(12):2731-3. PubMed ID: 11128654
[No Abstract] [Full Text] [Related]
38. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Patrono C; Patrignani P; García Rodríguez LA
J Clin Invest; 2001 Jul; 108(1):7-13. PubMed ID: 11435450
[No Abstract] [Full Text] [Related]
39. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
Kismet K; Akay MT; Abbasoglu O; Ercan A
Cancer Detect Prev; 2004; 28(2):127-42. PubMed ID: 15068837
[TBL] [Abstract][Full Text] [Related]
40. Cyclooxygenase-2: a target for the prevention and treatment of cancers of the upper digestive tract.
Altorki NK; Subbaramaiah K; Dannenberg AJ
Prog Exp Tumor Res; 2003; 37():107-23. PubMed ID: 12795051
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]